Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
-
New hope for transplant patients: drug targets fatty liver recurrence
Disease control Recruiting nowThis study tests a drug called resmetirom in people who have had a liver transplant and now have a fatty liver condition called MASH. The goal is to see if the drug can reduce liver fat safely. About 120 participants will receive either the drug or a placebo for 28 weeks.
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New registry tracks rezdiffra safety for moms and babies
Knowledge-focused Recruiting nowThis study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:06 UTC